Innate Pharma S.A. Gains 34%
Innate Pharma S.A. (IPHA:NASDAQ) jumped higher at $2.68, representing a gain of 34%. The stock got featured on our News Catalysts scanner on Fri, Jun 03, 2022 at 03:13 AM in the 'BIOTECH' category. From Tue, Jun 07, 2022, the stock recorded 22.22% Up Days and 10.00% Green Days
About Innate Pharma S.A. (IPHA:NASDAQ)
Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies.
Top 10 Gainers:
- RISE Education Cayman Ltd (REDU:NASDAQ), 138.46%
- Convey Health Solutions Holdings Inc. (CNVY:NYSE), 138.43%
- Valneva SE (VALN:NASDAQ), 93.14%
- Revlon, Inc. (REV:NYSE), 62.47%
- Great Panther Mining Limited (GPL:NYSEMKT), 51.8%
- G Medical Innovations Holdings Ltd. (GMVD:NASDAQ), 45.45%
- Clovis Oncology, Inc. (CLVS:NASDAQ), 38.98%
- CEA Industries Inc. (CEAD:NASDAQ), 38.24%
- Greenbox POS (GBOX:NASDAQ), 36.36%
- Innate Pharma S.A. (IPHA:NASDAQ), 34%